By Melanie Senior
Investors' calls for late-stage, lower-risk products and the promise of near-term revenues aren't new, either in European or US biotech. In Europe, however, having a revenue-generating arm has almost become...
European Biotech Is Specialty Pharma
Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.
More from Global Vision
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.